Jefferies Reiterates Buy Rating on Arcutis Biotherapeutics Inc. (ARQT) ahead of earnings

October 8, 2026 4:23 AM

Jefferies analyst Kambiz Yazdi reiterated a Buy rating and $39.00 price target on Arcutis Biotherapeutics Inc. (NASDAQ: ARQT).The analyst comments ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found